ABEONA THERAPEUTICS INC. Cash and Restricted Cash
ABEONA THERAPEUTICS INC. (ABEO) had Cash and Restricted Cash of $56.23 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.23M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.37M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.44M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $83.22M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $56.23M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $61.37M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $78.44M 10-K · filed 2026-03-17 |
| 2025-09-30 | $83.22M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $163.87M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $16.27M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $23.70M 10-K · filed 2026-03-17 |
| 2024-09-30 | $16.06M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $34.76M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $17.90M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $14.81M 10-K · filed 2025-03-20 |
| 2023-09-30 | $5.05M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $6.56M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $5.02M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $14.55M 10-K · filed 2024-03-18 |
| 2022-09-30 | $11.07M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $12.02M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $26.22M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $38.83M 10-K · filed 2023-03-29 |
| 2021-09-30 | $44.76M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $28.15M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $15.24M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $13.57M 10-K · filed 2022-03-31 |
| 2020-09-30 | $9.40M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $15.51M 10-Q · filed 2021-07-28 |
| 2020-03-31 | $41.27M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $130.37M 10-K · filed 2021-03-24 |
| 2019-09-30 | $49.03M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $43.72M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $27.03M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $19.31M 10-K · filed 2020-03-16 |
| 2018-09-30 | $34.16M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $50.55M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $132.28M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $138.03M 10-K · filed 2020-03-16 |
| 2017-09-30 | $56.52M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $58.30M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $63.21M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $69.14M 10-K · filed 2019-03-18 |
| 2015-12-31 | $40.14M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |